Is Macrophage Activation Syndrome in Kawasaki Disease Underrecognized?

REFERENCES

1. 1.↵
   1. McCrindle BW,
   2. Rowley AH,
   3. Newburger JW,
   4. Burns JC,
   5. Bolger AF,
   6. Gewitz M, et al.

   Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135:e927-e99.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Newburger JW,
   2. Takahashi M,
   3. Gerber MA,
   4. Gewitz MH,
   5. Tani LY,
   6. Burns JC, et al.

   Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Ogata S,
   2. Tremoulet AH,
   3. Sato Y,
   4. Ueda K,
   5. Shimizu C,
   6. Sun X, et al.

   Coronary artery outcomes among children with Kawasaki disease in the United States and Japan. Int J Cardiol 2013;168:3825-8.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Burns JC,
   2. Capparelli EV,
   3. Brown JA,
   4. Newburger JW,
   5. Glode MP.

   Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Durongpisitkul K,
   2. Soongswang J,
   3. Laohaprasitiporn D,
   4. Nana A,
   5. Prachuabmoh C,
   6. Kangkagate C.

   Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Ravelli A,
   2. Davì S,
   3. Minoia F,
   4. Martini A,
   5. Cron RQ.

   Macrophage activation syndrome. Hematol Oncol Clin North Am 2015; 29:927-41.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Ravelli A,
   2. Grom AA,
   3. Behrens EM,
   4. Cron RQ.

   Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289-98.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Muise A,
   2. Tallett SE,
   3. Silverman ED.

   Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003;112:e495.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Latino GA,
   2. Manlhiot C,
   3. Yeung RSM,
   4. Chahal N,
   5. McCrindle BW.

   Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010;32:527-31.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Simonini G,
    2. Pagnini I,
    3. Innocenti L,
    4. Calabri GB,
    5. De Martino M,
    6. Cimaz R.

    Macrophage activation syndrome/Hemophagocytic Lymphohistiocytosis and Kawasaki disease. Pediatr Blood Cancer 2010;55:592.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Wang W,
    2. Gong F,
    3. Zhu W,
    4. Fu S,
    5. Zhang Q.

    Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin Arthritis Rheum 2015;44:405-10.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Shafferman A,
    2. Birmingham JD,
    3. Cron RQ.

    High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J 2014;12:26.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. García-Pavón S,
    2. Yamazaki-Nakashimada MA,
    3. Báez M,
    4. Borjas-Aguilar KL,
    5. Murata C.

    Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol 2017;39:445-51.

    OpenUrl
14. 14.↵
    1. Choi UY,
    2. Han SB,
    3. Lee SY,
    4. Jeong DC.

    Should refractory Kawasaki disease be considered occult macrophage activation syndrome? Semin Arthritis Rheum 2017;46:e17.

    OpenUrl
15. 15.↵
    1. Henter JI,
    2. Horne A,
    3. Aricó M,
    4. Egeler RM,
    5. Filipovich AH,
    6. Imashuku S, et al.

    HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Ravelli A,
    2. Minoia F,
    3. Davì S,
    4. Horne A,
    5. Bovis F,
    6. Pistorio A, et al.

    2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol 2016;68:566-76.

    OpenUrl
17. 17.↵
    1. Verdoni L,
    2. Mazza A,
    3. Gervasoni A,
    4. Martelli L,
    5. Ruggeri M,
    6. Ciuffreda M, et al.

    An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395;1771-8..
18. 18.↵
    1. Riphagen S,
    2. Gomez X,
    3. Gonzalez-Martinez C,
    4. Wilkinson N,
    5. Theocharis P.

    Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607-8.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Ma L,
    2. Zhang YY,
    3. Yu HG.

    Clinical manifestations of Kawasaki disease shock syndrome. Clin Pediatr 2018;57:428-35.

    OpenUrl
20. 20.↵
    1. Burns JC,
    2. Koné-Paut I,
    3. Kuijpers T,
    4. Shimizu C,
    5. Tremoulet A,
    6. Arditi M.

    Review: found in translation: international initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki disease. Arthritis Rheumatol 2017;69:268-76.

    OpenUrl